What Is Cagrilintide?

How cagrilintide works

Amylin is a satiety hormone. It helps signal when you have eaten enough and moderates how quickly food leaves the stomach. Cagrilintide is engineered to activate the same amylin receptor complex (the calcitonin receptor with RAMPs), but with a longer duration of action suitable for less frequent dosing in research settings.

• Reduces appetite and food intake by enhancing satiety signalling
• Slows gastric emptying, which can help you feel fuller for longer
• Targets a different pathway to GLP‑1 medicines — a reason the two may be combined in studies

Why combine with GLP‑1? GLP‑1 agonists (such as semaglutide) and amylin analogues act on complementary appetite pathways. Early studies suggest the combination may produce greater average weight loss than GLP‑1 therapy alone. See: Cagrilintide vs Semaglutide and Cagrilintide vs Tirzepatide.

See potential benefits

What the research shows so far

Early‑phase clinical trials have reported meaningful reductions in body weight and hunger ratings with cagrilintide. In Phase 2 research, the combination of cagrilintide plus semaglutide produced larger average weight reductions over approximately 20–26 weeks than semaglutide alone in adults with overweight or obesity.

Important context:

• Data to date are from early‑stage trials; long‑term safety and durability still require confirmation in larger, longer studies.
• Not all individuals respond the same way; side effects and adherence affect outcomes.

Explore more detail: Cagrilintide Benefits, Results Timeline, How to read reviews and claims.

Get help interpreting the studies

Cagrilintide vs GLP‑1s and the “CagriSema” combination

GLP‑1 agonists like semaglutide and dual‑agonists like tirzepatide are approved in Australia for specific indications, whereas cagrilintide remains investigational. Mechanistically:

• GLP‑1s reduce appetite, slow gastric emptying, and improve glycaemic control via GLP‑1 receptors.
• Cagrilintide taps into the amylin pathway via amylin receptors.
• Combining the two (CagriSema) targets complementary appetite circuits and has, in trials, led to greater average weight loss than GLP‑1 alone over the study periods.

Compare pathways and study outcomes: Cagrilintide vs Semaglutide, Cagrilintide vs Tirzepatide, and broader GLP‑1 context in the GLP‑1 Australia Guide and Weight Loss Injections Australia.

Safety signals and side effects observed in studies

Side effects reported so far are mostly gastrointestinal and similar in profile to other appetite‑modulating injectables:

• Nausea, vomiting, diarrhoea or constipation
• Abdominal discomfort and reduced appetite
• Potential for delayed gastric emptying, which may affect absorption of oral medicines

Cautions commonly considered in this research area include a history of severe gastrointestinal disease (e.g., gastroparesis), pregnancy and breastfeeding (limited data), and careful review of other medications. As an investigational therapy, long‑term safety is still being established.

Learn more: Cagrilintide Side Effects and Dosage and study protocols.

Ask about safety and suitability

Is cagrilintide available in Australia?

As of now, cagrilintide is not TGA‑approved and is generally only accessible via clinical trials. Be cautious with grey‑market or “research chemical” offers — these often fall outside Australian medicine laws and may carry quality and legal risks.

• Is Cagrilintide Legal in Australia?
• Prescription considerations
• Buying guides and red‑flags
• Cost context (if and when access is available)

Approved alternatives that target appetite include GLP‑1 and dual‑agonist options: What Is Semaglutide?, What Is Tirzepatide?, What Is Retatrutide? (research stage).

Talk to an Australian provider

Who is cagrilintide being studied for?

Research has focused on adults with overweight or obesity, with or without type 2 diabetes. Primary goals include reducing hunger, improving satiety, and supporting clinically meaningful weight loss. Combination protocols with GLP‑1s seek to leverage complementary mechanisms for potentially greater effects.

Explore intent‑specific guides: Cagrilintide for Weight Loss, for Obesity, for Appetite Suppression, for Hunger Control, for Metabolic Health.

Frequently asked questions

Still unsure? Get expert help

Key takeaway

Cagrilintide is a long‑acting amylin analogue that targets appetite through a different pathway than GLP‑1 medicines. Early studies are promising for weight loss, especially in combination with semaglutide, but long‑term safety and access are still evolving. If you are exploring medical weight management, compare mechanisms, evidence and legal access before deciding next steps.

Get personalised guidance